Agomab Therapeutics has dosed the first patient in its global Phase 2b NOV-ERA study testing ontunisertib in about 320 patients with symptomatic Fibrostenosing Crohn's disease (FSCD). This randomized, placebo-controlled trial will evaluate three doses of ontunisertib over 52 weeks, aiming to improve bowel stricture passability. The study follows positive earlier Phase 2a results and could lead to the first targeted anti-fibrotic treatment for FSCD, a condition with no current approved therapies addressing fibrosis. Successful outcomes may support regulatory approval and new treatment options for patients with this progressive disease.
Agomab's Phase 2b study news comes as a backdrop to health sector trading on Pluang. Of 128 priced US health stocks, 28 rose and 100 fell as of Oct 14, 2026 03:02 WIB. Notable movers include INO at USD 1.00 with a -9.05% change and 95% buy orders, SANA at USD 2.40 down 8.59% with 92% buy orders, and ABEO at USD 4.52 down 7.76%.
Applied Materials projects sustained demand for its chipmaking equipment driven by AI infrastructure growth, expecting faster spending on wafer fab equipment through 2030. The company aims to increase its market share by over 2 percentage points from...
Gordon Haskett Capital Corporation set a $105 price target for Ollie's Bargain Outlet, suggesting an 18.1% upside from its current price around $89. The company’s board approved an additional $500 million share repurchase authorization, increasing to...
FRUIT Holdings, Inc. introduced PAVE, a new protocol designed to allow AI systems to call on human judgment and authority when needed. This approach ensures that human input retains its value, authority, and attribution within AI workflows, addressin...
AngioDynamics reported a 6.9% revenue increase to $80.9 million and a narrowed adjusted loss of 4 cents per share for Q1 fiscal 2027, with strong Med Tech sales growing 13.2%. Despite beating earnings expectations and improved gross margin, the stock...
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
